United States — Food and Drug Administration & Nathan Miller

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a Complete Response Letter to Aldeyra Therapeutics, citing a lack of substantial evidence for the efficacy of reproxalap, which triggered the stock price drop and subsequent lawsuits.

Nathan Miller: Nathan Miller is a Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, assisting with investor inquiries regarding the Aldeyra Therapeutics class action.

United States — Food and Drug Administration: The United States — Food and Drug Administration issued safety warnings concerning serious neurological complications in dogs treated with Bedinvetmab, which contributed to weakening prescription growth for Zoetis' product.

Nathan Miller: Nathan Miller is the Client Relations Manager for Bronstein, Gewirtz & Grossman, LLC, assisting investors in joining the class action lawsuit against Zoetis.

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to ImmunityBio regarding misleading efficacy claims made by Patrick Soon-Shiong about Anktiva, which triggered the stock price drop and subsequent lawsuits.

Nathan Miller: Nathan Miller is a Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, providing contact information for investors interested in the class action lawsuit.